Trials / Withdrawn
WithdrawnNCT06895941
Predictive Value of PET/CT for Efficacy of Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study was to investigate the enhancement of FAPI PET/CT metabolic parameters in predicting the efficacy performance of neoadjuvant immunotherapy using the pCR status of surgically resected specimens of lung cancer as the gold standard.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | PET | Exploring the predictive value of PET/CT metabolic parameters for the efficacy of neoadjuvant immunotherapy in non-small cell lung cancer. |
Timeline
- Start date
- 2025-04-30
- Primary completion
- 2027-04-01
- Completion
- 2027-04-01
- First posted
- 2025-03-26
- Last updated
- 2025-04-08
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06895941. Inclusion in this directory is not an endorsement.